Tailor study asco

The TAILORx Breast Cancer Trial - National Cancer Institute

★ ★ ★ ☆ ☆

The Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, is examining whether genes that are frequently associated with risk of recurrence for women with early-stage breast cancer can be used to assign patients to the most appropriate and effective treatment. The majority of women ...

The TAILORx Breast Cancer Trial - National Cancer Institute

TAILORx finds no chemotherapy benefit for most early ...

★ ★ ☆ ☆ ☆

Findings from the TAILORx clinical trial show chemotherapy does not benefit most women with early breast cancer. The new data, released at the 2018 ASCO annual meeting, will help inform treatment decisions for many women with early-stage breast cancer.

TAILORx finds no chemotherapy benefit for most early ...

TAILOR Study Demonstrates Efficacy of New Treatment in ...

★ ★ ☆ ☆ ☆

To our knowledge, the TAILOR trial (NCT01228734) is the first randomized, multicenter, phase III study of the addition of cetuximab to first-line FOLFOX prospectively choosing a RAS wt population and thus providing confirmative data for the efficacy and safety of cetuximab plus FOLFOX versus FOLFOX alone.

TAILOR Study Demonstrates Efficacy of New Treatment in ...

Erlotinib versus docetaxel as second-line treatment of ...

★ ★ ★ ★ ★

TAILOR is, to the best of our knowledge, the only study to investigate this issue in a direct comparison of docetaxel and erlotinib for second-line treatment after platinum-based chemotherapy. Our results show that docetaxel is more effective than erlotinib in this population.

Erlotinib versus docetaxel as second-line treatment of ...

Reports & Studies | ASCO

★ ★ ★ ☆ ☆

ASCO’s growing roster of highly respected, award-winning reports play an important role in informing the public, media, and government officials about the state of cancer care in America, advances in cancer care, and the need and means to accelerate cancer research. ASCO’s studies continue to provide the tools and resources to help make quality cancer care a reality for all

Reports & Studies | ASCO

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay ...

★ ★ ★ ★ ☆

Abstract Background The recurrence score based on the 21-gene breast cancer assay predicts chemotherapy benefit if it is high and a low risk of recurrence in the absence of chemotherapy if it is ...

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay ...

Merck Data at ASCO 2018 to Showcase Progress and Further ...

★ ★ ★ ☆ ☆

5/17/2018 · These long-term results include data on avelumab's duration of response and represent the first study to report long-term survival data for an immunotherapy in metastatic …

Merck Data at ASCO 2018 to Showcase Progress and Further ...

Training & Education | ASCO

★ ★ ★ ☆ ☆

ASCO’s growing roster of cutting-edge journals serves readers as the most credible, authoritative, peer-reviewed resources for significant clinical oncology research and research that informs the delivery of efficient, high-quality cancer care across the globe.

Training & Education | ASCO

Meeting Library | Meeting Library

★ ★ ★ ★ ☆

This content is made available for your personal use, educational advancement, or professional development. Unauthorized reproduction is prohibited. For permission to re-use for commercial or other purposes, please contact permissions@asco.org

Meeting Library | Meeting Library

SWOG sails into ASCO 2018 on a raft of research results ...

★ ★ ★ ★ ★

Researchers from SWOG, a cancer clinical trials group funded by the National Cancer Institute, will participate in 29 presentations to be made at the 54th Annual Meeting of the American Society of ...

SWOG sails into ASCO 2018 on a raft of research results ...

TAILORx at ASCO Annual Meeting | Genomic Health, Inc.

★ ★ ★ ★ ☆

For additional updates, you can follow us on Twitter (@GenomicHealth) and Facebook with #TAILORx.If you’ll be at ASCO this year, be sure to check out the presentation!. For those of you unable to attend ASCO or interested in learning more about the study results, we will be hosting a webinar on Monday, June 11 at 10 am PST. Hope you can join us!

TAILORx at ASCO Annual Meeting | Genomic Health, Inc.

Landmark TAILORx Results, Published Today in The New ...

★ ★ ★ ★ ☆

The TAILORx results will be published today in The New England Journal of Medicine in conjunction with a presentation during the Plenary Session at the 2018 American Society of Clinical Oncology ...

Landmark TAILORx Results, Published Today in The New ...

ASCO University | Lifelong Learning

★ ★ ★ ☆ ☆

The ASCO University Podcast is an audio-only weekly series that is focused on delivering updates for cancer treatment and care. Lymphoma: Multidisciplinary Molecular Tumor Boards A case-based activity including discussion of a 62-year-old woman with history of hypertension and monoclonal B …

ASCO University | Lifelong Learning

TAILORx trial finds most women with early breast cancer do ...

★ ★ ★ ★ ☆

New findings from the groundbreaking Trial Assigning Individualized Options for Treatment (Rx), or TAILORx trial, show no benefit from chemotherapy for 70 percent of women with the most common type of breast cancer. The study found that for women with hormone receptor (HR)-positive, HER2-negative ...

TAILORx trial finds most women with early breast cancer do ...

Prospective Validation of a 21-Gene Expression Assay in ...

★ ★ ☆ ☆ ☆

Study Patients. The study included women 18 to 75 years of age with axillary node–negative invasive breast cancer that was estrogen-receptor–positive or progesterone-receptor–positive (or ...

Prospective Validation of a 21-Gene Expression Assay in ...

ASCO: Erlotinib Worse Than Docetaxel for Wild-Type EGFR ...

★ ★ ★ ★ ☆

6/12/2012 · ASCO: Erlotinib Worse Than Docetaxel for Wild-Type EGFR NSCLC . Dave Levitan; ... In the TAILOR study, investigators randomized patients to either erlotinib 150 mg/day or chemotherapy with docetaxel 75 mg/m 2 or 35 mg/m 2. Of 702 patients registered, 554 were genotyped, 222 were randomized, and 219 were eligible for the final analysis (110 ...

ASCO: Erlotinib Worse Than Docetaxel for Wild-Type EGFR ...

Tailoring Chemotherapy Decisions - TAILORx Study Results ...

★ ★ ★ ☆ ☆

6/4/2018 · 4 June 2018 The American Society of Clinical Oncology (ASCO) annual meeting, a gathering of over 40,000 oncology specialists, was held this past weekend in Chicago. One of the studies that received a significant amount of press attention was the TAILORx study. There are several genomic tests which evaluate a tumor’s DNA to better determine how aggressive that tumor is,…

Tailoring Chemotherapy Decisions - TAILORx Study Results ...

Abstracts | Gastrointestinal Cancers Symposium

★ ★ ★ ★ ☆

Review ASCO's abstract polices and submission requirements, as well as important dates in the abstract timeline. Abstract Submission Key Dates. September 25, 2018 at 11:59 PM EDT Abstract submission deadline. Early November 2018 ... Abstracts are released on ...

Abstracts | Gastrointestinal Cancers Symposium

Gastrointestinal Cancers Symposium

★ ★ ★ ★ ☆

Thank you for helping to make the Gastrointestinal Cancers Symposium a success. Join us again next year, January 23-25, 2020, in San Francisco.

Gastrointestinal Cancers Symposium

Results of Phase III TAILOR study shows Erbitux (cetuximab ...

★ ★ ★ ☆ ☆

Merck has announced that the pivotal Chinese Phase III TAILOR study met its primary endpoint of significantly increasing progression-free survival (PFS) in patients with RAS wild-type metastatic colorectal cancer (mCRC) treated with Erbitux (cetuximab) plus …

Results of Phase III TAILOR study shows Erbitux (cetuximab ...

ASCO 2018: Dr. Burris Highlights TAILORx and More in ...

★ ★ ★ ★ ★

Howard “Skip” A. Burris, III, MD, chief medical officer, Sarah Cannon Research Institute, 2019 ASCO president-elect, and a 2014 Giant of Cancer Care® in Drug Development, discusses breast ...

ASCO 2018: Dr. Burris Highlights TAILORx and More in ...

Trials and Outcomes: Accelerating Precision Medicine at ...

★ ★ ★ ★ ☆

6/2/2017 · Comprehensive genomic profiling offers the opportunity to tailor treatment to each patient. At this year’s ASCO Annual Meeting, we are presenting data demonstrating the potential clinical impact of CGP. In this study we assessed the effect of matched versus unmatched therapy on clinical outcomes (overall survival).

Trials and Outcomes: Accelerating Precision Medicine at ...

ASCO 2018 - News - Merck global

★ ★ ★ ☆ ☆

Merck data at ASCO 2018 to showcase progress and further optionality of oncology pipeline. Merck today announced new data from a number of high priority clinical development programs across its oncology portfolio to be presented at this year’s American Society of Clinical Oncology Annual Meeting.

ASCO 2018 - News - Merck global

LUNG CANCER At ASCO: DOCETAXEL BETTER THAN ERLOTINIB …

★ ★ ★ ★ ☆

6/13/2012 · lung cancer at asco: docetaxel better than erlotinib for nsclc – tailor study Share on Twitter Share on Facebook Share on Google+ Share on LinkedIn Erlotinib is not as effective as docetaxel in NSCLC patients without EFGR mutations.

LUNG CANCER At ASCO: DOCETAXEL BETTER THAN ERLOTINIB …

News from ASCO 2018 | SWOG

★ ★ ★ ☆ ☆

6/8/2018 · The 2018 ASCO annual meeting brought important news for patients. The big headline, of course, highlighted results from TAILORx, the breast cancer study with stunning results – thousands of women with early stage breast cancer can safely skip chemotherapy.

News from ASCO 2018 | SWOG

Chemo Not Needed for Most Early Breast Cancer: TAILORx

★ ★ ★ ★ ☆

The results come from a federally funded study, ... "The goal was to tailor treatment and they chose the title [TAILORx] very applicably," he added. ... American Society of Clinical Oncology (ASCO ...

Chemo Not Needed for Most Early Breast Cancer: TAILORx

Impact of the 2018 ASCO/CAP HER2 guidelines update for ...

★ ★ ★ ★ ★

Recently, the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) updated the guidelines on HER2 testing for invasive breast cancer. Little is known about the impact of the guidelines update. We aimed to study the impact of the 2018 ASCO/CAP HER2 testing guidelines update.

Impact of the 2018 ASCO/CAP HER2 guidelines update for ...

ASCO - oncotypeiq.com

★ ★ ★ ☆ ☆

Primary Study Objective Results Presented. At the ASCO 2018 Plenary Session, lead investigator Joseph A. Sparano, MD, presented results for the primary TAILORx study objective, which determines if adjuvant hormonal therapy is not inferior to adjuvant chemohormonal therapy in women whose tumors fall into the Primary Study Group category (an Oncotype DX Breast Recurrence Score® result of 11 to 25).

ASCO - oncotypeiq.com

Stroke subtype classification: A comparative study of ASCO ...

★ ★ ★ ☆ ☆

3/15/2012 · Stroke subtype classification: A comparative study of ASCO and modified TOAST. ... Frequency of different grades of ASCO phenotypes in the study population. ASCO phenotype Disease present (ASCO 1, 2, 3) ... We use cookies to help provide and enhance our service and tailor …

Stroke subtype classification: A comparative study of ASCO ...
Jaoa-case-report-study.html,Java-ap-exam-study-guide.html,Jay-belsky-daycare-study.html,Jcyte-study-abroad.html,Jensen-bible-self-study-guides.html